Related Experiment Video
Updated: May 2, 2026
Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice
Published on: December 21, 2019
[Peritoneal malignant mesothelioma: review and recent data]
Éliane Mery1, Juliette Hommell-Fontaine2, Mathieu Capovilla3
1Département d'anatomie pathologique, institut Claudius-Regaud, 20, 24, rue du Pont-Saint-Pierre, 31052 Toulouse, France.
Abstract:
Peritoneal malignant mesothelioma is a rare tumor, less common than its pleural counterpart. It develops from the mesothelial cells overlying peritoneum and preferentially occurs in male, with an average age ranging from 47 to 60.5 years. Asbestos whose impact is less strong than in pleural mesothelioma, SV 40 virus, chronic peritonitis could be implicated as factors favoring the development of peritoneal mesothelioma. Clinical symptoms are not specific, and the imagery remains little or not contributive. The 2004 WHO classification recognizes 3 different types, which differ in terms of presentation and prognosis: diffuse epithelioid mesothelioma (the most common), sarcomatoid mesothelioma and biphasic mesothelioma. Many variants are described within these groups. Immunohistochemistry is mandatory to affirm or disprove peritoneal malignant mesothelioma diagnosis, based on a panel of antibodies divided in positive markers and negative markers. Indeed an accurate diagnosis is necessary to define a therapeutic strategy more and more frequently based on the combination of radical surgery and hyperthermic intra peritoneal chemotherapy. Such an approach significantly improves the prognosis of these aggressive diseases.
Insights
Peritoneal malignant mesothelioma is a rare cancer. Accurate diagnosis using immunohistochemistry is crucial for effective treatment combining surgery and hyperthermic chemotherapy, improving patient outcomes.
Area of Science:
- Oncology
- Pathology
Background:
- Peritoneal malignant mesothelioma is a rare neoplasm originating from peritoneal mesothelial cells.
- It predominantly affects males aged 47-60.5 years, with potential links to asbestos exposure, SV40 virus, and chronic peritonitis.
- Clinical presentation and imaging are often non-specific, complicating early diagnosis.
Purpose of the Study:
- To provide an overview of peritoneal malignant mesothelioma.
- To discuss its classification, diagnostic challenges, and therapeutic strategies.
Main Methods:
- Review of the 2004 World Health Organization (WHO) classification of peritoneal mesothelioma.
- Emphasis on the indispensable role of immunohistochemistry for diagnosis.
- Discussion of treatment modalities.
Main Results:
- The 2004 WHO classification identifies three main types: diffuse epithelioid, sarcomatoid, and biphasic mesothelioma, each with variants.
- Immunohistochemistry is essential for accurate diagnosis, utilizing specific antibody panels.
- Combined radical surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) is a promising therapeutic approach.
Conclusions:
- Accurate diagnosis of peritoneal malignant mesothelioma is critical for treatment planning.
- The combination of surgery and HIPEC offers improved prognosis for this aggressive malignancy.
